#### **Title: Integrating Gut Microbiota and Host Immune Markers for Highly** 1

#### Accurate Diagnosis of *Clostridioides difficile* Infection 2

- 3
- Authors: Shanlin Ke<sup>1,2</sup>, Nira R. Pollock<sup>3,4</sup>, Xu-Wen Wang<sup>1</sup>, Xinhua Chen<sup>5</sup>, Kaitlyn Daugherty<sup>5</sup>, 4
- Qianyun Lin<sup>5</sup>, Hua Xu<sup>5</sup>, Kevin W. Garey<sup>6</sup>, Anne J. Gonzales-Luna<sup>6</sup>, Ciarán P. Kelly<sup>5</sup>\*, Yang-Yu 5 Liu<sup>1,7</sup>\*
- 6

#### 7 **Affiliations:**

- <sup>1</sup>Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical 8
- 9 School, Boston, Massachusetts 02115, USA.
- 10 <sup>2</sup>State Key Laboratory of Pig Genetic Improvement and Production Technology, Jiangxi
- Agricultural University 330045, China. 11
- 12 <sup>3</sup>Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical
- Center, Boston, Massachusetts 02115, USA. 13
- 14 <sup>4</sup>Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts 02115, 15 USA.
- 16 <sup>5</sup>Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center,
- Boston, Massachusetts 02115, USA. 17
- 18 <sup>6</sup>Department of Pharmacy Practice and Translation Research, University of Houston College of
- Pharmacy, Houston, Texas 77204, USA. 19
- <sup>7</sup>Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 20
- 21 02115, USA.
- 22 \*To whom correspondence should be addressed: Y.-Y.L. (yyl@channing.harvard.edu) or C.P.K.
- (ckelly2@bidmc.harvard.edu). 23
- 24
- One Sentence Summary: Incorporating both gut microbiome and host immune marker data into 25 classification models can better distinguish CDI from other groups than can either type of data 26
- 27 alone.
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36

Abstract: Exposure to *Clostridioides difficile* can result in asymptomatic carriage or infection with symptoms ranging from mild diarrhea to fulminant pseudomembranous colitis. A reliable diagnostic approach for C. difficile infection (CDI) remains controversial. Accurate diagnosis is paramount not only for patient management but also for epidemiology and disease research. Here, we characterized gut microbial compositions and a broad panel of innate and adaptive immunological markers in 243 well-characterized human subjects, who were divided into four phenotype groups: CDI, Asymptomatic Carriage, Non-CDI Diarrhea, and Control. We found that CDI is associated with alteration of many different aspects of the gut microbiota, including overall microbial diversity and microbial association networks. We demonstrated that incorporating both gut microbiome and host immune marker data into classification models can better distinguish CDI from other groups than can either type of data alone. Our classification models display robust diagnostic performance to differentiate CDI from Asymptomatic carriage (AUC~0.916), Non-CDI Diarrhea (AUC~0.917), or Non-CDI that combines all other three groups (AUC~0.929). Finally, we performed symbolic classification using selected features to derive simple mathematic formulas for highly accurate CDI diagnosis. Overall, this study provides evidence supporting important roles of gut microbiota and host immune markers in CDI diagnosis, which may also inform the design of future therapeutic strategies. 

#### 73 INTRODUCTION

74 *Clostridioides difficile* infection (CDI) is the most common cause of healthcare–associated

- infection and an important cause of morbidity and mortality among hospitalized patients<sup>1-3</sup>.
- 76 Current treatment strategies for CDI, including vancomycin, metronidazole and fidaxomicin,
- 77 have inconsistent cure rates and treatment failure or CDI recurrence may occur in approximately
- 78 one third of cases<sup>4,5</sup>. Antibiotic exposure is considered the most important factor predisposing
- 79 patients to CDI<sup>6,7</sup>. In fact, treatments with antibiotics have a tremendous impact on the
- 80 composition and functionality of the gut microbiota, and accordingly are associated with reduced
- 81 colonization resistance against pathogens such as C. *difficile*<sup>8-10</sup>. A distinct microbial community
- structure has been reported to be associated with CDI in human cohorts and animal models $^{11,12}$ .
- 83 Characterization of the microbial features in individuals with different C. difficile
- 84 infection/colonization status is an essential step in understanding the role of the gut microbiome
- 85 in the development of CDI.
- 86 The pathophysiology of CDI is mainly associated with the production of two exotoxins,
  87 toxin A (TcdA) and toxin B (TcdB)<sup>13</sup>. TcdA and TcdB act on intestinal epithelial cells, inducing
- 88 pro-inflammatory cytokines, loss of tight junctions, cell detachment and an impaired mucosal
- barrier<sup>14-16</sup>. The innate and adaptive immune responses to CDI play crucial roles in disease onset,
- 90 expression, severity, progression, and overall  $prognosis^{17,18}$ . The innate immune defense
- 91 mechanisms against *C. difficile* and its toxins include the commensal intestinal flora, mucosal
- 92 barrier, intestinal epithelial cells, and mucosal immune system<sup>19,20</sup>. TcdA and TcdB have
- 93 multiple effects on the innate immune system, including inducing expression of numerous pro-
- 94 inflammatory mediators (e.g., cytokines, chemokines and neuroimmune peptides) and the
- 95 recruitment and activation of a variety of innate immune  $cells^{21,22}$ . Adaptive immunity is also
- 96 sufficient to provide some protection from CDI, likely via antibody-mediated neutralization of
- 97 TcdA and TcdB $^{23-26}$ . These immune markers also have the potential to act as clinically useful
- 98 diagnostic markers of CDI.
- 99 Exposure to toxinogenic *C. difficile* can lead to a range of clinical outcomes ranging from
  100 asymptomatic colonization to mild diarrhea and more severe disease syndromes such as
- 101 pseudomembranous colitis, toxic megacolon, bowel perforation, sepsis, and death $^{27,28}$ .
- 102 Asymptomatic *C. difficile* carriage is characterized by *C. difficile* colonization in the absence of 103 symptoms of infection. Previous studies suggest that *C. difficile* asymptomatic carriers have the
- potential to contribute to *C. difficile* transmission and hospital-onset CDI in inpatient facilities, as carriers can shed spores into the hospital environment<sup>29,30</sup>.
- The diagnosis of CDI is based on clinical signs and symptoms in combination with
  laboratory testing. Several diagnostic laboratory tests are available including enzyme
  immunoassays (EIA) for TcdA and TcdB, nucleic acid amplification tests (NAAT), selective
  toxinogenic culture, cell cytotoxicity neutralization assay, and glutamate dehydrogenase EIA<sup>31-33</sup>.
- 110 However, currently available approaches do not accurately differentiate CDI from diarrhea with
- another cause in a patient colonized with toxinogenic *C. difficile*. Over-diagnosis of disease
- 112 could result in overtreatment of CDI, delayed recognition of other causes of illness, and
- 113 unnecessary antibiotic exposures<sup>34</sup>.

114 Machine learning has a great impact in many areas of medical research, as it offers a 115 principled approach for developing sophisticated, automatic, and objective algorithms for 116 analysis of complex data. Indeed, previous studies indicate that supervised learning can be 117 successfully employed for clinical disease assessment for diverse disorders including Parkinson's disease<sup>35</sup>, diabetes<sup>36</sup>, inflammatory bowel disease<sup>37</sup> and glaucoma<sup>38</sup>. In our previous work, we 118 found that specific immune markers, particularly G-CSF, can be used to distinguish adults with 119 120 CDI from other groups including asymptomatic carriers and NAAT-negative patients with and 121 without diarrhea<sup>39</sup>. Here, we integrate the host immune marker data and newly obtained gut

- microbiome data from subjects of the same cohort to build classification models to optimally distinguish CDI from other groups. Our aim is to identify consistent biological signatures for
- 124 highly accurate diagnosis of CDI.
- 125

## 126 **RESULTS**

## 127 Baseline demographic and clinical characteristics of participants

- 128 Our clinical cohort consists of 243 well-characterized recruited participants, who were divided
- into four groups (see Materials and Methods)<sup>39</sup>: (1) Control: subjects without diarrhea and with
- 130 NAAT-negative stool (n=47); (2) Non-CDI Diarrhea: subjects with diarrhea but NAAT-negative
- stool (n=44); (3) Asymptomatic Carriage: subjects without diarrhea but with NAAT-positive
- stool (n=40); (4) CDI: subjects with diarrhea and NAAT-positive stool (n=112). The first three
- 133 groups can be combined as the Non-CDI group. The entire clinical cohort had a mean  $\pm$  SD age
- 134 of  $63.66 \pm 14.85$  year and was 48.15% female. Demographic data of the cohort are summarized
- in Table 1. In total, 187 participants (76.95%) had both gut microbiome and immune marker data
- 136 available (see Table S1).
- 137

## 138 Microbial community structure

- 139 To compare the overall microbial community structure of the four groups, we first calculated the
- alpha diversity (i.e., the within-sample taxonomic diversity) of each sample at the genus level
- 141 using four different measures: *taxa richness* (the observed number of different taxa present in the
- sample), *Chaol* (abundance-based estimator of taxa richness), *Evenness* (the uniformity of the
- 143 population size of each taxa present in the sample), and *Shannon diversity index* (estimator of
- taxa richness and evenness: more weight on richness). (See Materials and Methods for detailed
- 145 definitions of those alpha diversity measures.) As shown in Fig.1, We found that richness indices
- 146 (taxa richness and Chao1) did not differ significantly among these groups. The gut microbiota of
- 147 Non-CDI Diarrhea subjects showed lower evenness than that of the Control group. Shannon
- 148 diversity was significantly lower in the Non-CDI Diarrhea and CDI groups than in the Control
  140 group
- 149 group.
- 150 To determine whether the gut microbial compositions of participants are affected by *C*.
- 151 *difficile* infection/colonization status, we performed Principal Coordinates Analysis (PCoA) at
- the genus level using Bray-Curtis dissimilarity (which is a beta diversity measure to quantify the
- 153 between-sample compositional dissimilarity). We found no distinct clusters corresponding to the

154 four different phenotype groups, implying that the gut microbial compositions of participants

155 from the four groups are not significantly different (Fig. 2A). Interestingly, by directly

156 comparing the beta diversity of each group, we did find that the CDI group displays higher beta

157 diversity than other groups (Fig. 2B), indicating that the microbial compositions of participants

158 within the CDI group vary more prominently than other groups. Permutational multivariate

analysis of variance (PERMANOVA) showed that the overall bacterial composition differed

significantly among different groups based on the CDI status (P < 0.001; Table S2), whereas

161 other host factors such as age, sex, race and ethnicity had no significant effect on the microbiome

162 composition.

163 To identify microbiome markers (i.e., certain taxa with very high discriminatory ability)

to differentiate those different phenotype groups, we performed differential abundance analysis.

165 In particular, we used ANCOM<sup>40</sup> (analysis of composition of microbiomes) with a Benjamini-

166 Hochberg correction, and adjusted for age and sex. We found that the abundances of 15 genera

167 were significantly different between CDI and Asymptomatic Carriage groups (Fig. 3A and Table

168 S3). Among the 15 genera, 4 of them (*Veillonella, Enterobacter, Granulicatella* and *Dialister*) of

169 these genera were enriched in the CDI group, while the other 11 genera (*Lactococcus, Dorea*,

170 Moryella, [Ruminococcus] gauvreauii group, Stenotrophomonas, Agathobacter, Blautia,

171 Sellimonas, Eggerthella, Faecalitalea and Lachnospiraceae UCG-008) were enriched in the

172 Asymptomatic Carriage group. We also found 16 differentially abundant genera between the

173 Non-CDI Diarrhea group and the CDI group (Fig. 3B and Table S4). Of these, 10 genera

174 (Clostridioides, Enterobacter, Epulopiscium, Escherichia-Shigella, Eisenbergiella, Dialister,

175 Ruminiclostridium, Fusobacterium, Klebsiella and Veillonella) were enriched in the CDI group,

and the other 6 genera ([*Eubacterium*]\_hallii\_group, Collinsella, Agathobacter, Dorea,

177 *Stenotrophomonas and Streptococcus*) were enriched in the Non-CDI Diarrhea group. ANCOM

analysis also enabled us to identify 40 genera (including *Clostridioides* and *Veillonella*) that have

significant differential abundances between the CDI group and the whole Non-CDI group (Fig.

180 3C and Table S5). Note that a total of 6 differentially abundant genera were identified from all

181 the three comparisons: CDI vs. Asymptomatic Carriage; CDI vs. Non-CDI Diarrhea; CDI vs.

182 Non-CDI. Among them, *Veillonella*, *Enterobacter* and *Dialister* were enriched in the CDI group,

183 while *Dorea*, *Stenotrophomonas* and *Agathobacter* were depleted in the CDI group.

184

# 185 Microbial correlation networks

186 To compare the microbial communities of the four groups at the network-level, we constructed

187 the genus-level microbial correlation network for each group using SparCC<sup>41</sup> (sparse correlations

188 for compositional data). We found that the microbial correlation network of the CDI group has

189 quite different structure compared to other groups (Fig. 4). In order to quantify the difference of

190 the network structure, we calculated the number of nodes, number of edges, average degree (the

average number of connections per node), graph density (measure of how close the network is toa complete graph), clustering coefficient (measure of how complete the neighborhood of a node

a complete graph), clustering coefficient (measure of now complete the neighborhood of a node

is) and modularity (measure of how well a network decomposes into modular communities)

194 (Table S6). In general, compared with the networks of other groups, the network of the CDI 195 group has fewer nodes and edges, lower average degree, but higher modularity. These indicate 196 that the overall microbial correlations in the CDI group are much weaker than those in other 197 groups.

To analyze these patterns in more detail, we used NetShift<sup>42</sup> to identify potentially 198 important "driver" taxa responsible for the change of microbial correlations. This analysis 199 200 revealed 24 potential driver taxa linked with the change of microbial correlations between CDI 201 and Asymptomatic Carriage groups (Fig. S1). The top driver taxa were Alistipes, Clostridioides, 202 Desulfovibrio, Eggerthella, Ervsipelatoclostridium, Klebsiella, Odoribacter Proteus, 203 [Ruminococcus] torques group, Streptococcus, Vagococcus and Veillonella. We then identified 204 24 genera as potential driver taxa underlying the change of microbial correlations between CDI 205 and Non-CDI Diarrhea groups (Fig. S2). The top driver taxa were Alistipes, Buttiauxella, 206 Citrobacter, Clostridium sensu stricto 13, Desulfovibrio, Klebsiella, Oscillibacter, 207 Phascolarctobacterium, Streptococcus and Veillonella. Finally, Netshift analysis revealed 38 208 potential driver taxa underlying the change of microbial correlations between CDI and Non-CDI groups. The top driver taxa were Bifidobacterium, Clostridioides, Klebsiella, Oscillibacter, 209 Streptococcus and Veillonella (Fig. S3). Together, these results suggested that certain bacterial 210 211 taxa (e.g., Clostridioides, Klebsiella, Streptococcus and Veillonella) could play an important role 212 in driving the changes of microbial correlations in subjects with different C. difficile 213 infection/colonization status.

214

#### 215 Host immune markers and CDI

216 To determine the systemic levels of proinflammatory cytokines in CDI, we measured the

- circulating levels of granulocyte-colony stimulating factor (G-CSF), interleukin-1β (IL-1β), IL-2, 217
- IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, monocyte chemoattractant protein-1 (MCP-1), vascular 218
- endothelial growth factor-A (VEGF-A), and tumor necrosis factor-alpha (TNF- $\alpha$ ) as previously 219
- reported<sup>39</sup>. Serum concentrations of immunoglobulin A (IgA), IgG, and IgM antibodies against 220
- 221 C. difficile toxin A and toxin B were measured by semi-quantitative enzyme-linked
- immunosorbent assay (ELISA). We previously demonstrated specific markers of these innate 222
- and adaptive immunity that can distinguish CDI from each of the other three groups<sup>39</sup>. In the 223
- current study, we are particularly interested in comparing the CDI group and the combined Non-224
- CDI group. Based on the Mann-Whitney U test, we identified in total 11 immune markers that 225
- displayed significantly different concentrations in these two groups, including G-CSF, IL-4, IL-226
- 6, IL-8, IL-10, IL-15, TNF-α, MCP1, IgA anti-toxin A and B, and IgG anti-toxin A in blood 227
- (Table S7). All of these immune markers had higher concentrations in the CDI group than in the 228
- Non-CDI group. Host immune marker variations between samples were evaluated using the 229 230
- Principal Component Analysis (PCA) (Fig. 2C). PCA plot showed no clear clustering of those
- subjects based on immune marker concentrations. However, boxplot of Euclidean distance of 231
- 232 immune marker profiles from CDI patients showed higher within-group variation than that in all
- 233 the other three groups (Fig. 2D). PERMANOVA analysis indicated that the immune homeostasis

was significantly different among different groups based on the CDI status (P = 0.016; Table

S2). But age, gender, race and ethnicity did not have significant effects on the host immune

- and marker levels.
- 237

#### 238 Interplay between gut microbiome and host immune markers

- To reveal the interplay between the gut microbiome and the host immune system, we calculated
- 240 the correlations between microbial compositions (at the genus level) and the circulating levels of
- 241 host immune markers for each of the four groups (Spearman correlation with Benjamini-
- Hochberg correction). The results are shown in Fig. 5 and Fig. S4. For the Control group, the
- 243 most significant associations were identified as *Chiristensenellaceae R-7 group* negatively
- associated with TNFα, *Bifidobacterium* positively associated with VEGFA and IL-13, *Rothia*
- positively associated with IL-15, and *Veillonella* positively related with IL-4 (Fig.5A and Fig.
- 246 S4). For the Non-CDI Diarrhea group, *Ruminococcaceae UCG-011* was negatively correlated
- 247 with IL-8 and IL-6, *Defluviitaleaceae UCG-011* was positively correlated with IL-1b, and
- 248 *Blautia* was negatively correlated with MCP1 levels (Fig. 5B). For the Asymptomatic Carriage
- 249 group, we found that *Lactobacillus* was negatively associated with VEGFA, *Akkermansia* was
- 250 positively associated with IL-6, and *Enterococcus* was positively related to TNFα (Fig. 5C). For
- the CDI group, negative associations involved *Akkermansia* and IL-10, *Lactococcus* and G-CSF,
- while positive associations involved *Lactobacillus* and IgG and IgA anti-toxin B (Fig. 5D).
- 253 Interestingly, none of these most significant associations was universally present across different
- 254 groups. This indicated that the interactions between gut microbiota and host immunological
- 255 markers can be very sensitive to the status of *C. difficile* colonization and infection. More
- 256 importantly, this result implies that the integration of gut microbiota and host immune markers
- 257 might be quite useful for highly accurate diagnosis of CDI.
- 258

# Diagnostic accuracy for CDI classification based on host immune markers and gut microbiota

- 261 To determine whether host immune markers or gut microbiota could serve as biomarkers to
- 262 classify subjects into different groups, we constructed a multi-class classifier based on random
- 263 forests (RF). One of the most popular performance metrics of a classifier is the Area Under the
- 264 receiver operating characteristic Curve (AUC). The performance of a multi-class classifier is
- 265 measured by both micro-average and macro-average AUCs. (For micro-average AUC, we
- 266 calculated the AUC from the individual true positive rates and false positive rates of the multi-
- class model. For the macro-average AUC, we calculated the AUC independently for each class
- and then took the average.) We considered three different feature types: (1) host immune maker
- concentrations alone; (2) gut microbial compositions alone; and (3) the integration of (1) and (2)
- in our classification analysis. To eliminate confounding effects, we excluded the genus
- 271 *Clostridioides* from our classification analysis. The immune marker-based classifier achieved
- 272 macro-average AUC ~ 0.827 and micro-average AUC ~ 0.828 (Fig. S5A), which are quite
- 273 comparable to the performance of microbiota-based classifier (Fig. S5B). Interestingly,

integrating immune marker with gut microbiota showed much better classification performance (macro-average AUC  $\sim 0.926$  and micro-average AUC  $\sim 0.869$ ) (Fig. S5C).

We further performed binary classifications to distinguish CDI subjects from
Asymptomatic Carriage, Non-CDI Diarrhea, and Non-CDI subjects, using different feature types
(Fig. 6). The goal of this analysis was to assess whether any single taxon or immune marker
could reliably differentiate CDI status. The importance of each feature was quantified by the
Mean Decrease in Accuracy (MDA) of the classifier due to the exclusion (or permutation) of this
feature. The more the accuracy of the classifier decreases due to the exclusion (or permutation)
of a single feature, the more important that feature is deemed for classification of the data.

283 In the classification of CDI vs. Asymptomatic Carriage, we found that G-CSF and 284 Morvella were the most important immune and microbial features, respectively (Fig. S6:A-B). But the classification based on G-CSF (or *Morvella*) alone did not yield very high performance: 285 286 mean AUC  $\sim 0.817$  (or 0.701), respectively (Fig. 6:A1-A2). When we used all the immune 287 markers (or all the genera) as features, we achieved mean AUC  $\sim 0.867$  (or 0.805), respectively (Fig. 6:A3-A4). Interestingly, when we integrated all the host immune markers and gut microbial 288 composition data together, we achieved a much higher performance with mean AUC  $\sim 0.900$ 289 (Fig. 6:A5). In order to select a subset of features that is as discriminatory as the whole set of 290 291 features, we followed the "1-SE" rule (i.e., one chooses the model with fewest features such that 292 its classification performance is less than one standard error away from that of the model with all 293 the features), and selected the following 4 features: 2 bacterial genera (Morvella and Veillonella) 294 and 2 immune markers (G-CSF and IL-6) in classifying CDI and Asymptomatic Carriage groups 295 (Fig. S6:G-J). The RF classifier with those selected features displayed an outstanding 296 classification performance, with mean AUC  $\sim 0.916$  (Fig. 6:A6). Note that a significant negative correlation between Morvella and G-CSF was found in the Asymptomatic Carriage group (Fig. 297

5C), which might contribute to the outstanding performance of the RF classifier with *Moryella* and G-CSF as selected features.

300 In the classification of CDI vs. Non-CDI Diarrhea groups, we found that G-CSF and [Eubacterium] hallii group are the top immune and microbial features, respectively (Fig. S6:C-301 D). But the classification based on G-CSF (or [Eubacterium] hallii group) alone did not 302 perform very well: mean AUC ~ 0.747 (or ~ 0.630), respectively (Fig. 6:B1-B2). When we used 303 304 all the immune marker (or all the microbial genera) as features, we achieved mean AUC  $\sim 0.851$ (or  $\sim 0.884$ ), respectively (Fig. 6:B3-B4). By integrating all features from both host immune 305 marker and gut microbial genera, we further improved the classification performance to mean 306 AUC ~ 0.918 (Fig. 6:B5). Following the "1-SE" rule, we selected the following 5 features: 3 307 genera: Enterococcus, Epulopiscium and [Eubacterium] hallii group; and 2 immune markers: 308 G-CSF and IgA anti-toxin A (Fig. S6:H-K). The RF classifier with those selected features 309 achieved mean AUC ~ 0.917 (Fig. 6:B6), which is quite comparable to that of using all the 310 features. Note that Enterococcus was found to be significantly associated with G-CSF in the 311 312 Non-CDI Diarrhea group (Fig. 5B). This might partially explain the outstanding performance of 313 the RF classifier with Enterococcus and G-CSF as selected features.

314 In the classification of CDI vs. Non-CDI groups, we found that G-CSF and Curvibacter are the top immune and microbial features, respectively (Fig. S6:E-F). Classification based on G-315 CSF (or *Curvibacter*) alone achieved mean AUC ~ 0.802 (or ~ 0.683), respectively (Fig. 6:C1-316 317 C2). When we used all the immune marker (or all the microbial genera) as features, we achieved 318 mean AUC ~ 0.878 (or ~ 0.903), respectively (Fig. 6:C3-C4). Integrating all features from both host immune marker and gut microbial genera, we further improved the classification 319 performance to mean AUC ~ 0.941 (Fig. 6:C5). Following the "1-SE" rule, we selected the 320 following 10 features: 6 genera: Stenotrophomonas, Curvibacter, Enterobacter, Anaerobacillus, 321 Fusobacterium and Veillonella; and 4 immune markers: G-CSF, IL-6, TNF-α and IgA anti-toxin 322

- B (Fig. S6:I-L). Classification with those well selected features achieved mean AUC  $\sim 0.929$
- 324 (Fig. 6:C6).

325

#### 326 Using symbolic classification to derive diagnostic scores.

The outstanding classification results based on well-selected features prompt us to derive simplemathematical models for CDI diagnosis. To achieve that, we leveraged symbolic classification

 $(SC)^{43,44}$ , a genetic programming technique that automatically searches the space of

330 mathematical expressions to find the model that best fits a given dataset. The fitness function in

331 SC is a maximization function, and the number of generations is chosen based on the saturation

of the fitness score (Fig. S7). Using the same set of selected features and trained with the entire

- dataset, the SC model outperformed logistic regression (LR) in differentiating CDI from
- Asymptomatic Carriage (or Non-CDI Diarrhea, or Non-CDI), based on various performance
   metrics: Accuracy, Precision, Recall and F1-score (see Table 2).

Indeed, as shown in Table 2, we derived a simple SC model with selected features, reaching a very high accuracy (0.896) in distinguishing CDI subjects from Asymptomatic Carriage. Basically, for each subject *i*, we calculate the diagnostic score f(i) that will be used for CDI diagnosis: the class of subject *i* is CDI if f(i) > 0; Asymptomatic Carriage, if  $f(i) \le 0$ .

340 Here,

$$f(i) = x_{GCSF} * x_{Veillonella} (x_{GCSF}^3 - 0.2 * x_{Moryella} + 0.4) + 1.1 * x_{GCSF} - 0.1 * x_{IL6} - 18.25,$$
(1)

- 343 with  $x_a$  representing the abundance or concentration of feature-*a* in subject-*i*. Similarly, we
- derived a SC model with accuracy of 0.900 in distinguishing CDI (if f(i) > 0) from Non-CDI

345 Diarrhea (if  $f(i) \le 0$ ) with the diagnostic score

346 
$$f(i) = x_{Enterococcus} * x_{IgA\_toxA} \left( 0.5 * x_{Epulopiscium} - 1 \right) + x_{[Eubacterium]\_hallii\_group} \left( 0.02 * -x_{GCSF} \right) + x_{IgA\_toxA} \left( 1 - \frac{10}{x_{GCSF}} \right) - \frac{0.003}{x_{Enterococcus}}.$$
 (2)

- Finally, we derived a SC model with accuracy of 0.882 in distinguishing CDI (if f(i) > 0) from
- 349 Non-CDI (if  $f(i) \le 0$ ) with the diagnostic score
- 350  $f(i) = x_{\text{GCSF}} * x_{\text{IgA}_{\text{toxB}}} (0.2 * x_{\text{Anaerobacillus}} * x_{\text{GCSF}} * x_{\text{Stenotrophomonas}} * x_{\text{TNF}\alpha} + 0.04 *$
- 351  $x_{Curvibacter} * x_{GCSF} + 0.3 * x_{Enterobacter}^4 * x_{GCSF} * x_{Veillonella} + x_{Fusobacterium} *$

352 
$$x_{GCSF}(0.5 * x_{Curvibacter} + x_{GCSF} * x_{Stenotrophomonas}) + x_{Curvibacter}(0.1 * x_{IL6} - x_{Anaerobacillus}) + x_{Stenotrophomonas}(x_{Stenotrophomonas} - 2).$$
(3)

354 To ensure the SC models learned from the entire dataset are not overfitting, we performed cross-validation by randomly splitting the dataset to form a training set (80% of the 355 356 data) and a held-out test set (20% of the data) in 10 different ways. Each time, for each 357 classification task, we learned the SC model from the training dataset and evaluated it on the test 358 dataset. Due to the different training sets, SC will derive different mathematical formulas (i.e., diagnostic scores). However, those SC models learned from different training datasets 359 demonstrated quite robust performance in terms of Accuracy, Precision, Recall and F1-score (see 360 361 Table S8). More importantly, even trained with less data, the SC models still outperformed LR 362 models learned from the entire dataset.

These SC models consisted of explicit mathematical equations, which are more transparent than black-box classifiers such as RF. At the same time, the SC models are also more accurate than traditional classifiers (such as LR). The transparency and high accuracy highlight

- the importance of SC models in the clinical diagnosis of CDI.
- 367

#### 368 **DISCUSSION**

369 Current methods for CDI diagnosis are unable to combine high sensitivity and high clinical

- 370 specificity, which can result in either underdiagnosis or overdiagnosis of CDI<sup>45</sup>. A more accurate
- 371 diagnostic approach for CDI could optimize therapeutic decision-making and reduce
- transmission. Here, we employed 16S rRNA gene sequencing to profile the gut microbial
- 373 compositions and combined the gut microbiome data with data from a broad panel of innate and
- adaptive host immune response markers to investigate the potential roles of these markers in the
- diagnosis of CDI. We demonstrated that the combination of host immune markers and gut
- 376 microbial data can provide a potential route to optimize CDI diagnosis. Importantly, this work
- derived specific diagnostic models (in terms of mathematic equations) that yielded robust
- accuracy in differentiating CDI subjects from Asymptomatic Carriage, Non-CDI Diarrhea andNon-CDI groups.

Taxonomic diversity is a fundamental property of ecological systems. It is generally
 believed to be an important determinant of the structure and functioning of ecological

- 382 communities<sup>46,47</sup>. Diversity indices have been routinely calculated in the study of human
- 383 microbiome<sup>48</sup>. Consistent with previous studies<sup>49-52</sup>, we found that the gut microbiomes of CDI
- 384 patients were characterized by lower Shannon diversity than that of the Control group.
- 385 Interestingly, we observed an increased variation of both immune markers and gut microbial
- 386 compositions in the CDI group with respective to other studied groups. This suggests that CDI is
- 387 characterized by a significantly less stable microbiome and immune homeostasis. Our findings
- are in line with the Anna Karenina principle, which suggests that CDI linked changes in the
- microbiome and immune homeostasis are likely stochastic, leading to community instability 53-55.
- We were able to identify several candidate driver taxa (e.g., *Desulfovibrio, Klebsiella, Streptococcus* and *Veillonella*) that played a key role in driving the changes of microbial

392 correlation networks between CDI and Asymptomatic Carriage (or Non-CDI Diarrhea, Non-

CDI) groups. Among those driver taxa, *Desulfovibrio* has previously been shown to have a

pathogenic role in ulcerative colitis due to its ability to generate sulfides<sup>56</sup>. *Streptococcus* has

395 previously been shown to produce lactate thus impacting C. *difficile* TcdA production and *tcdA* 

expression to alleviate CDI<sup>57</sup>. *Klebsiella* is a Gram-negative bacterium that cause different types

397 of healthcare-associated infections including pneumonia, bloodstream infections, and

meningitis<sup>58</sup>. *Klebsiella* bacteria have been increasingly shown to develop antimicrobial
resistance, most recently to the class of antibiotics known as carbapenems<sup>59,60</sup>. It is thus possible
that the CDI pathogenesis is further enforced by the enrichment of antagonistic bacteria present
in the gut microbiome of CDI subjects. In addition, our analysis demonstrated that the
associations between host immunological markers and gut microbial compositions in the CDI

group were dramatically different from those in other groups. However, further investigations areneeded to determine whether these alterations are integral to the CDI pathogenesis.

405 The diagnosis of CDI remains challenging, especially the ability to distinguish CDI and C. difficile colonization  $^{61-63}$ . To address this issue, we developed classification models aimed at 406 differentiating CDI status based on host immune markers and gut microbiome data. We excluded 407 the genus *Clostridioides* in further classification analysis to eliminate confounding effects. 408 Evaluating the classification performance of host immune markers or/and microbiome data in 409 410 multi-class models, it appears that a combination of host immune markers and gut microbiome 411 data can further improve the accuracy of classification. More specifically, we were able to 412 identify specific immune and microbial features that could accurately distinguish CDI subjects 413 from Asymptomatic Carriage, Non-CDI Diarrhea, and Non-CDI subjects. In addition, most of

the selected features identified by feature selection were also differentially abundant genera anddifferentially expressed immune markers.

From the classification of CDI and Asymptomatic Carriage, we were able to select a few 416 features with outstanding discriminability, including Veillonella and Morvella. Interestingly, a 417 positive relationship between Veillonella and CDI has been identified in recent studies<sup>64-67</sup>. An 418 419 important role for Veillonella in CDI is supported by the fact that Veillonella species were associated with low coprostanol levels that correlated strongly with CDI<sup>64</sup>. A similar negative 420 relationship between Moryella species and CDI has previously been observed<sup>68</sup>. Enterococcus, a 421 422 feature selected from the classification of CDI vs. Non-CDI Diarrhea, has been reported to be associated with CDI due to vancomycin resistance<sup>69</sup>. Consistent with the findings from previous 423 reports<sup>70,71</sup>, *Epulopiscium* was significantly enriched in the CDI group and played an important 424 role in differentiating this comparison. Among those features selected from the classification of 425 CDI and Non-CDI groups, Enterobacter and Fusobacterium have been considered as 426 427 opportunistic pathogens involved in multiple diseases<sup>72,73</sup>. Machine learning method has the potential to identify biomarkers and aid in the diagnosis 428

- 429 of many diseases. However, the learnt relationships between predictors and outcome are
- 430 typically non-transparent, especially non-linear methods (i.e., decision tree learning). Previous
- 431 study has shown that an interpretable trees framework can extract, measure, prune, select, and

432 summarize rules from a tree ensemble, and calculates frequent variable interactions<sup>74</sup>. However,

these rules from tree ensembles are still too complicated to be clinically meaningful. Classical

434 logistic regression, is one of the most common machine learning models in medicine<sup>75</sup>. The main

435 drawback of LR is its failure to solve non-linear problems and it underperforms where there are

436 multiple or non-linear decision boundaries<sup>76</sup>. Furthermore, the log odds scale in LR is hard to

437 interpret<sup>77</sup>. Symbolic classification based on genetic programming is an automated technique to
 438 derive formulas from features for classification purpose<sup>78</sup>. Using the selected integrated features

from the random forests model, we demonstrated that the mathematical formulas automatically

440 derived from symbolic classification have robust diagnostic accuracy to differentiate CDI

441 patients from Asymptomatic Carriage (or Non-CDI Diarrhea, and Non-CDI groups).

442 Specifically, symbolic classification provides explicit mathematic formulas as its output, which

significantly improves the transparency of the learned relationship between predictors and

outcomes. These results hold translational promise in clinical diagnosis of CDI. Further external
validation of the derived formulas will require a different cohort with the same inclusion criteria

as ours. This is beyond the scope of the current work.

We previously demonstrated the potential clinical utility of a specific immunological
biomarker (G-CSF) for CDI diagnosis<sup>39</sup>. This study leverages the newly obtained gut
microbiome data from the same unique and well-characterized study cohort, allowing us to study
integrated host immune marker and gut microbiome signatures. The fundamental differences
between this study and our previous one are the clinical utilization of integrated immune and
microbiome signatures to distinguish CDI patients from Asymptomatic Carriage, Non-CDI

453 Diarrhea, and Non-CDI groups, and to derive diagnostic scores for CDI diagnosis. We believe

that this study sets the stage to explore the potential role of an immune and microbiome-based

455 test for CDI diagnosis. Of course, observed associations and selected features do not offer any

456 causal relationships. Prospective studies are needed to validate the mechanism underlying the

relationship between these selected features/biomarkers and the CDI infection/colonization
status. The 16S rRNA sequencing may not have captured additional insights associated with the

disease status available at the species or strain level. Further studies are needed to validate the

460 clinical utility of the proposed biomarkers by metagenomics sequencing as well as

461 metatranscriptomics, metaproteomics and metabolomics.

462 In summary, leveraging a well-characterized clinical cohort, we provided strong evidence that integrating gut microbiome and host immune signatures can significantly improve the CDI 463 diagnosis. In particular, these results demonstrate that knowledge of gut microbial compositions 464 in combination with host immune markers is beneficial in generating clinically relevant machine 465 learning models for disease diagnosis. Indeed, the machine learning models show high diagnostic 466 467 accuracy in differentiating true CDI from asymptomatic carriage of C. difficile and from non-C. difficile diarrhea, which are areas where current laboratory testing for CDI lacks adequate 468 469 clinical specificity.

470

# 472 MATERIALS AND METHODS

#### 473 Study cohort

- 474 The background and design of this cohort has been described in details previously<sup>62</sup>. Concisely,
- 475 we have four groups associated with different *C. difficile* infection/colonization statuses: (1)
- 476 Control: subjects without diarrhea who had screened as eligible for the asymptomatic carriage
- 477 group (see below) but were NAAT-negative on research stool testing; (2) Non-CDI Diarrhea:
- 478 subjects with diarrhea but NAAT-negative stool on clinical testing; (3) Asymptomatic Carriage:
- 479 subjects were admitted for at least 72 hours, had received at least one dose of an antibiotic within
- 480 the past 7 days, did not have diarrhea in the 48 hours prior to stool sample collection, had
- 481 positive NAAT results on research stool testing and were not treated for CDI; (4) CDI: inpatients
- 482 with positive clinical stool NAAT result, diarrhea, and a decision to treat for CDI. All subjects
- 483 were adults (age  $\geq$  18 years old). Clinical serum samples were collected as discards within 24
- 484 hours of stool sample collection. In our previous study<sup>39</sup>, the four groups were named as (1) "no
- 485 Diarrhea NAAT-Negative" = Control; (2) diarrhea NAAT-negative = Non-CDI Diarrhea; (3)
- 486 Carrier-NAAT = Asymptomatic Carriage and (4) CDI-NAAT = CDI. In this work, for simplicity
- 487 we used the simpler and more clearly descriptive titles.
- 488

## 489 Serum immune marker measurement

- 490 The measurement of host serum cytokines concentrations of IL-2, IL-4, IL-6, IL-8, IL-10, IL-13,
- 491 IL-15, IL-1 $\beta$ , G-CSF, IL-1 $\beta$ , MCP-1, VEGF-A, and TNF- $\alpha$  was performed using a Milliplex
- 492 magnetic bead kit and Luminex analyzer (MAGPIX) (Millipore Sigma, Inc., Burlington, MA) as
- 493 per the manufacturer's instructions. Purified toxin A and B were separately prepared from *C*.
- 494 *difficile* strain VPI 10463 (American Type Culture Collection 43255-FZ, Manassas, VA). Serum
- 495 antibody (IgA, IgG, and IgM) levels against *C. difficile* toxins A and B were measured by semi-
- 496 quantitative enzyme-linked immunosorbent assay (ELISA). All the experimental details have
- 497 been reported previously  $^{39,62}$ .
- 498

# 499 Fecal DNA extraction and bacterial 16S rRNA sequencing data analysis

- 500 Stool DNA was extracted using the DNeasy PowerSoil Pro Kit (Qiagen, cat# 12888-100) in a
- 501 QiaCube automated DNA extraction system (Qiagen) according to instructions. Briefly, 250mg
- stool was transferred into a PowerBead Pro Tube provided with the kit and 200 ug RNaseA and
- 503 800 μl of CD1 solution were added. Tubes were vortexed briefly, transferred into an adapter, and
- then vortexed at maximum speed for 10 min. Tubes were centrifuged at 15,000 x g for 1 min and
- about 500–600 μl supernatant was used for DNA extraction according to instructions. DNA were
- 506 eluted in 70  $\mu$ l elution solution C6 and stored at -80<sup>o</sup>C until use. 16S rRNA microbiome
- 507 characterization was performed by sequencing the V4 region of the 16S rRNA gene using the
- 508 Illumina MiSeq.<sup>79</sup> Each sample was amplified using a barcoded primer, which yielded a unique
- 509 sequence identifier tagged onto each individual sample library. Illumina-based sequencing
- 510 yielded greater than 15,000 reads per sample. CLC Genomics Workbench version 12 (Qiagen)
- 511 was used for OTU clustering and generation of abundance tables. Analyses were performed

- using the tutorial "OTU Clustering Step by Step" updated September 2, 2019 and available on
- 513 the Qiagen website:
- 514 <u>https://resources.qiagenbioinformatics.com/tutorials/OTU\_Clustering\_Steps.pdf</u>
- 515

#### 516 Microbial diversity and differential abundance analysis

- 517 Both alpha and beta diversity measures were calculated at the genus level using the vegan:
- 518 Community Ecology Package in R (https://CRAN.R-project.org/package=vegan). Measures of
- alpha diversity included: the richness S (the number of taxa present in the community/sample),

520 Chao 1 index  $S_{chao1} = S + \frac{F_1(F_1-1)}{2(F_2+1)}$ , Shannon index  $H = -\sum_{i=1}^{S} p_i \log p_i$ , and evenness J =

- 521 *H*/log*S*. Here,  $F_1$  and  $F_2$  are the count of singletons and doubletons, respectively, and  $p_i$  is the
- relative abundance of taxon-*i* in the community. For beta diversity, we used the Bray-Curtis

523 dissimilarity measure, which was also used in the Principal Coordinates Analysis (PCoA). We

applied principal component analysis (PCA) on the expression levels of all immune markers

- 525 based on the Euclidean distance.
- Difference in microbiome compositions and immune expression levels by CDI status (i.e., different groups) and other covariates (i.e., age, sex, race and ethnicity) were tested by the permutational multivariate analysis of variance (PERMANOVA) using the "adonis" function in the vegan R package. All PERMANOVA tests were performed with the default 999 permutations based on the Bray-Curtis dissimilarity and Euclidean distance for microbial composition and immune marker data, respectively. Note that in the PERMANOVA tests, we
- only included subjects with known information of age, sex, race and ethnicity.
- For differential abundance analysis, we used ANCOM<sup>40</sup> (analysis of composition of
  microbiomes), with a Benjamini–Hochberg correction at 5% level of significance, and adjusted
  for age and sex. The Mann–Whitney U test was used to compare the difference of immune
  marker levels between different groups.
- 537

#### 538 Microbial correlation network analysis

- 539 The microbial correlation networks were constructed using SparCC <sup>41</sup> (sparse correlations for
- 540 compositional data, <u>https://github.com/luispedro/sparcc</u>). Significant interactions were
- 541 determined by the bootstrapped results (N = 100) using the script PseudoPvals in SparCC.
- 542 Significant correlations with absolute sparse correlations  $\ge 0.3$  were visualized using Gephi
- 543 (https://gephi.org/). We also used the NetShift<sup>42</sup> (https://web.rniapps.net/netshift) to identify
- 544 potential "driver" taxa underlying the differences of microbial correlation networks associated
- 545 with CDI and Asymptomatic Carriage (or Non-CDI Diarrhea, and Non-CDI). The key driver
- taxa were identified based on the neighbor shift (NESH) score, Jaccard Index and delta
- 547 betweenness  $(\Delta B)^{42}$ .
- 548

## 549 Microbiome-Immune marker association analysis

- 550 Associations between the gut microbiota and host immune markers were quantified by Spearman
- 551 correlation coefficients in combination with Benjamini-Hochberg FDR correction to account for

552 multiple hypothesis testing (significance threshold  $\alpha \le 0.05$ ). All included genera were required 553 to be detected in  $\ge 50\%$  of all samples in each group.

554

## 555 Classification with Random Forests model

To build a classification model capable of testing the overall contribution of immunological or 556 microbial data in distinguishing the CDI status, we developed a multi-class random forests (RF) 557 558 classifier. The data is split into a training set and a test set, with 70% of the data forming the 559 training data and the remaining 30% forming the test set. The performance of the multi-class 560 model was measured by micro-average and macro-average AUC. A macro-average score computed the metric independently for each group and then was averaged across all levels 561 562 regardless of the number of samples in each group, whereas a micro-average will aggregate the 563 contributions of all groups to compute the average metric.

564 To determine whether more specific host immune markers or gut microbial taxa could 565 differentiate CDI subjects from Asymptomatic Carriage, Non-CDI Diarrhea and Non-CDI 566 groups, we constructed the binary classifiers based on RF models with integrated immune 567 markers and microbiome data. The performance of the classifiers were evaluated by a 5-fold 568 cross validation. In order to reduce computation complexity and feature redundancy, a feature selection procedure was performed as follows. We first ranked all the features based on their 569 570 mean decrease accuracy (MDA). Then we followed the "1-SE strategy" to select the minimum 571 set of top features whose mean AUC is within one standard error of the mean AUC from the 572 model with all of the features.

573

#### 574 Symbolic classification with genetic programming

575 Genetic programming (GP) is a genetic algorithm that searches the space of mathematical equations without any constraints on their forms<sup>80</sup>. GP involves reproduction, random mutation, 576 577 crossover, a fitness function, and multiple generations of evolution of a population of computer programs to resolve a given task. GP is commonly used to investigate a functional relationship 578 579 (i.e., a mathematical formula) between features in data (symbolic regression: SR) or to group 580 data into categories (symbolic classification: SC). We employed Karoo GP<sup>81</sup>, a genetic programming application suite written in Python that support both SR and SC analysis, to derive 581 582 simple formulas for CDI diagnosis. We performed a random data-split to create a training set 583 (80% of the data) and a held-out test set (20% of the data) for ten times, which were used to evaluate the SC performance. Due to the different training sets, SC will derive different 584 585 formulas, but their classification performances (in terms of Accuracy, Precision, Recall, F1-586 score) are quite comparable (Table S8). The formulas shown in Table 2 were derived based on 587 the whole dataset. The Karoo GP was used with the following settings: (1) the fitness function 588 (Kernel) is c (representing "classification"); (2) the type of tree is r (ramped half/half); (3) the 589 maximum tree depth for the initial population is 6; (4) the number of trees per generation is 100; 590 (5) the maximum number of generations is 190 (based on the converging results shown in Fig. 591 S7); (6) constants include 0.1, 0.2, 0.3, 0.4 and 0.5; and (7) all other parameters are set as default

592	values. The fitness function in SC is a maximization function, which will seek the highest fitness
593	score among the trees in each generation. The sign of the final formula $f(i)$ will be used for CDI
594	diagnosis: the class of subject i is CDI if $f(i) > 0$ ; or Asymptomatic Carriage (or Non-CDI
595	Diarrhea, Non-CDI) if $f(i) \leq 0$ .
596	To demonstrate the advantage of SC, for each classification task (i.e., CDI vs.
597	Asymptomatic Carriage, CDI vs. Non-CDI Diarrhea, and CDI vs. Non-CDI), we also performed
598	logistic regression (LR) using the same set of selected features as used in SC (Table 2). The LR
599	models were constructed using the glm() function in R. The class of subject $i$ is CDI if
600 601	$p(t) \ge 0.5$ ; or Asymptomatic Carriage (or Non-CDI Diarriea, Non-CDI) if $p(t) < 0.5$ .
602	
603	
604	
605	
606	
607	
608	
609	
610	
611	
612	
613	
614	
615	
616	
617	
618	
619	
620	
621	
622	
623	
624	
625	
626	
627	

# 628 **REFERENCES AND NOTES**

- Lessa, F. C. *et al.* Burden of Clostridium difficile infection in the United States. *N Engl J Med* 372, 825-834, doi:10.1056/NEJMoa1408913 (2015).
- 631 2 Depestel, D. D. & Aronoff, D. M. Epidemiology of Clostridium difficile infection. J
  632 Pharm Pract 26, 464-475, doi:10.1177/0897190013499521 (2013).
- McDonald, L. C. *et al.* Clinical Practice Guidelines for Clostridium difficile Infection in
  Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA)
  and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 66, e1e48, doi:10.1093/cid/cix1085 (2018).
- 637 4 Bagdasarian, N., Rao, K. & Malani, P. N. Diagnosis and treatment of Clostridium
  638 difficile in adults: a systematic review. *JAMA* 313, 398-408,
  639 doi:10.1001/jama.2014.17103 (2015).
- 640 5 Rineh, A., Kelso, M. J., Vatansever, F., Tegos, G. P. & Hamblin, M. R. Clostridium
  641 difficile infection: molecular pathogenesis and novel therapeutics. *Expert Rev Anti Infect*642 *Ther* 12, 131-150, doi:10.1586/14787210.2014.866515 (2014).
- 643 6 Stevens, V., Dumyati, G., Fine, L. S., Fisher, S. G. & van Wijngaarden, E. Cumulative
  644 antibiotic exposures over time and the risk of Clostridium difficile infection. *Clin Infect*645 *Dis* 53, 42-48, doi:10.1093/cid/cir301 (2011).
- Slimings, C. & Riley, T. V. Antibiotics and hospital-acquired Clostridium difficile
  infection: update of systematic review and meta-analysis. *J Antimicrob Chemother* 69, 881-891, doi:10.1093/jac/dkt477 (2014).
- 649 8 Lewis, B. B. *et al.* Loss of Microbiota-Mediated Colonization Resistance to Clostridium
  650 difficile Infection With Oral Vancomycin Compared With Metronidazole. *J Infect Dis*651 212, 1656-1665, doi:10.1093/infdis/jiv256 (2015).
- Becattini, S., Taur, Y. & Pamer, E. G. Antibiotic-Induced Changes in the Intestinal
  Microbiota and Disease. *Trends Mol Med* 22, 458-478,
  doi:10.1016/j.molmed.2016.04.003 (2016).
- Buffie, C. G. *et al.* Profound alterations of intestinal microbiota following a single dose
  of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. *Infect Immun* 80, 62-73, doi:10.1128/IAI.05496-11 (2012).
- Perez-Cobas, A. E. *et al.* Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. *Front Microbiol* 5, 335, doi:10.3389/fmicb.2014.00335 (2014).
- Theriot, C. M. *et al.* Antibiotic-induced shifts in the mouse gut microbiome and
  metabolome increase susceptibility to Clostridium difficile infection. *Nat Commun* 5,
  3114, doi:10.1038/ncomms4114 (2014).
- Leffler, D. A. & Lamont, J. T. Clostridium difficile Infection. *N Engl J Med* 373, 287 288, doi:10.1056/NEJMc1506004 (2015).
- Genth, H., Dreger, S. C., Huelsenbeck, J. & Just, I. Clostridium difficile toxins: more
  than mere inhibitors of Rho proteins. *Int J Biochem Cell Biol* 40, 592-597,
  doi:10.1016/j.biocel.2007.12.014 (2008).
- Sun, X., He, X., Tzipori, S., Gerhard, R. & Feng, H. Essential role of the
  glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha
  by macrophages. *Microb Pathog* 46, 298-305, doi:10.1016/j.micpath.2009.03.002 (2009).

672 16 Riegler, M. et al. Clostridium difficile toxin B is more potent than toxin A in damaging 673 human colonic epithelium in vitro. J Clin Invest 95, 2004-2011, doi:10.1172/JCI117885 674 (1995). 675 17 Sun, X. & Hirota, S. A. The roles of host and pathogen factors and the innate immune 676 response in the pathogenesis of Clostridium difficile infection. Mol Immunol 63, 193-202, 677 doi:10.1016/j.molimm.2014.09.005 (2015). 678 18 Kelly, C. P. & Kyne, L. The host immune response to Clostridium difficile. J Med 679 Microbiol 60, 1070-1079, doi:10.1099/jmm.0.030015-0 (2011). 19 Bibbo, S. et al. Role of microbiota and innate immunity in recurrent Clostridium difficile 680 681 infection. J Immunol Res 2014, 462740, doi:10.1155/2014/462740 (2014). 682 20 Iacob, S., Iacob, D. G. & Luminos, L. M. Intestinal Microbiota as a Host Defense 683 Mechanism to Infectious Threats. Front Microbiol 9, 3328, 684 doi:10.3389/fmicb.2018.03328 (2018). 685 21 Madan, R. & Petri, W. A., Jr. Immune responses to Clostridium difficile infection. Trends Mol Med 18, 658-666, doi:10.1016/j.molmed.2012.09.005 (2012). 686 687 22 Sun, X., Savidge, T. & Feng, H. The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) 2, 1848-1880, doi:10.3390/toxins2071848 (2010). 688 689 23 Kyne, L., Warny, M., Qamar, A. & Kelly, C. P. Association between antibody response 690 to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357. 189-193, doi:10.1016/S0140-6736(00)03592-3 (2001). 691 692 24 Wilcox, M. H. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile 693 Infection. N Engl J Med 376, 305-317, doi:10.1056/NEJMoa1602615 (2017). 694 25 Giannasca, P. J. et al. Serum antitoxin antibodies mediate systemic and mucosal 695 protection from Clostridium difficile disease in hamsters. Infect Immun 67, 527-538 696 (1999). Johnston, P. F., Gerding, D. N. & Knight, K. L. Protection from Clostridium difficile 697 26 infection in CD4 T Cell- and polymeric immunoglobulin receptor-deficient mice. Infect 698 Immun 82, 522-531, doi:10.1128/IAI.01273-13 (2014). 699 700 27 Rupnik, M., Wilcox, M. H. & Gerding, D. N. Clostridium difficile infection: new 701 developments in epidemiology and pathogenesis. Nat Rev Microbiol 7, 526-536, doi:10.1038/nrmicro2164 (2009). 702 703 28 Schaffler, H. & Breitruck, A. Clostridium difficile - From Colonization to Infection. Front Microbiol 9, 646, doi:10.3389/fmicb.2018.00646 (2018). 704 705 29 Blixt, T. et al. Asymptomatic Carriers Contribute to Nosocomial Clostridium difficile 706 Infection: A Cohort Study of 4508 Patients. Gastroenterology 152, 1031-1041 e1032, 707 doi:10.1053/j.gastro.2016.12.035 (2017). Guerrero, D. M. et al. Asymptomatic carriage of toxigenic Clostridium difficile by 708 30 709 hospitalized patients. J Hosp Infect 85, 155-158, doi:10.1016/j.jhin.2013.07.002 (2013). Tenover, F. C., Baron, E. J., Peterson, L. R. & Persing, D. H. Laboratory diagnosis of 710 31 711 Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn 13, 573-582, doi:10.1016/j.jmoldx.2011.06.001 (2011). 712 713 Burnham, C. A. & Carroll, K. C. Diagnosis of Clostridium difficile infection: an ongoing 32 conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 26, 604-630, 714 doi:10.1128/CMR.00016-13 (2013). 715

716	33	Musher, D. M. et al. Detection of Clostridium difficile toxin: comparison of enzyme
717		immunoassay results with results obtained by cytotoxicity assay. J Clin Microbiol 45,
718		2737-2739, doi:10.1128/JCM.00686-07 (2007).
719	34	Kociolek, L. K. et al. Impact of a Healthcare Provider Educational Intervention on
720		Frequency of Clostridium difficile Polymerase Chain Reaction Testing in Children: A
721		Segmented Regression Analysis. J Pediatric Infect Dis Soc 6, 142-148,
722		doi:10.1093/jpids/piw027 (2017).
723	35	Abos, A. et al. Discriminating cognitive status in Parkinson's disease through functional
724		connectomics and machine learning. Sci Rep 7, 45347, doi:10.1038/srep45347 (2017).
725	36	Dagliati, A. et al. Machine Learning Methods to Predict Diabetes Complications. J
726		Diabetes Sci Technol 12, 295-302, doi:10.1177/1932296817706375 (2018).
727	37	Mossotto, E. et al. Classification of Paediatric Inflammatory Bowel Disease using
728		Machine Learning. Sci Rep 7, 2427, doi:10.1038/s41598-017-02606-2 (2017).
729	38	Kim, S. J., Cho, K. J. & Oh, S. Development of machine learning models for diagnosis of
730		glaucoma. PLoS One 12, e0177726, doi:10.1371/journal.pone.0177726 (2017).
731	39	Kelly, C. P. et al. Host Immune Markers Distinguish Clostridioides difficile Infection
732		From Asymptomatic Carriage and Non-C. difficile Diarrhea. Clin Infect Dis,
733		doi:10.1093/cid/ciz330 (2019).
734	40	Mandal, S. et al. Analysis of composition of microbiomes: a novel method for studying
735		microbial composition. Microb Ecol Health Dis 26, 27663, doi:10.3402/mehd.v26.27663
736		(2015).
737	41	Friedman, J. & Alm, E. J. Inferring correlation networks from genomic survey data. PLoS
738		Comput Biol 8, e1002687, doi:10.1371/journal.pcbi.1002687 (2012).
739	42	Kuntal, B. K., Chandrakar, P., Sadhu, S. & Mande, S. S. 'NetShift': a methodology for
740		understanding 'driver microbes' from healthy and disease microbiome datasets. ISME J
741		<b>13</b> , 442-454, doi:10.1038/s41396-018-0291-x (2019).
742	43	Bannister, C. A., Halcox, J. P., Currie, C. J., Preece, A. & Spasic, I. A genetic
743		programming approach to development of clinical prediction models: A case study in
744		symptomatic cardiovascular disease. PLoS One 13, e0202685,
745		doi:10.1371/journal.pone.0202685 (2018).
746	44	Schmidt, M. & Lipson, H. Distilling free-form natural laws from experimental data.
747		Science 324, 81-85, doi:10.1126/science.1165893 (2009).
748	45	Gateau, C., Couturier, J., Coia, J. & Barbut, F. How to: diagnose infection caused by
749		Clostridium difficile. Clin Microbiol Infect 24, 463-468, doi:10.1016/j.cmi.2017.12.005
750		(2018).
751	46	Loreau, M. et al. Biodiversity and ecosystem functioning: current knowledge and future
752		challenges. Science 294, 804-808, doi:10.1126/science.1064088 (2001).
753	47	Ives, A. R. & Carpenter, S. R. Stability and diversity of ecosystems. Science 317, 58-62,
754		doi:10.1126/science.1133258 (2007).
755	48	Ma, Z. S., Li, L. & Gotelli, N. J. Diversity-disease relationships and shared species
756		analyses for human microbiome-associated diseases. ISME J 13, 1911-1919,
757		doi:10.1038/s41396-019-0395-y (2019).
758	49	Song, Y. et al. Microbiota dynamics in patients treated with fecal microbiota
759		transplantation for recurrent Clostridium difficile infection. PLoS One 8, e81330,
760		doi:10.1371/journal.pone.0081330 (2013).

761	50	Milani, C. et al. Gut microbiota composition and Clostridium difficile infection in
762		hospitalized elderly individuals: a metagenomic study. Sci Rep 6, 25945,
763		doi:10.1038/srep25945 (2016).
764	51	Jiang, Z. D. et al. Randomised clinical trial: faecal microbiota transplantation for
765		recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from
766		a small pool of healthy donors delivered by colonoscopy. <i>Aliment Pharmacol Ther</i> 45,
767		899-908, doi:10.1111/apt.13969 (2017).
768	52	Shankar, V. et al. Species and genus level resolution analysis of gut microbiota in
769		Clostridium difficile patients following fecal microbiota transplantation. <i>Microbiome</i> <b>2</b> ,
770		13, doi:10.1186/2049-2618-2-13 (2014).
771	53	Zaneveld, J. R., McMinds, R. & Vega Thurber, R. Stress and stability: applying the Anna
772		Karenina principle to animal microbiomes. Nat Microbiol 2, 17121,
773		doi:10.1038/nmicrobiol.2017.121 (2017).
774	54	Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME
775		J 5, 82-91, doi:10.1038/ismej.2010.92 (2011).
776	55	Caussy, C. et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver
777		disease. Nat Commun 10, 1406, doi:10.1038/s41467-019-09455-9 (2019).
778	56	Rowan, F. et al. Desulfovibrio bacterial species are increased in ulcerative colitis. Dis
779		Colon Rectum 53, 1530-1536, doi:10.1007/DCR.0b013e3181f1e620 (2010).
780	57	Kolling, G. L. et al. Lactic acid production by Streptococcus thermophilus alters
781		Clostridium difficile infection and in vitro Toxin A production. Gut Microbes 3, 523-529,
782		doi:10.4161/gmic.21757 (2012).
783	58	van de Beek, D. et al. Clinical features and prognostic factors in adults with bacterial
784		meningitis. N Engl J Med 351, 1849-1859, doi:10.1056/NEJMoa040845 (2004).
785	59	Arnold, R. S. et al. Emergence of Klebsiella pneumoniae carbapenemase-producing
786		bacteria. South Med J 104, 40-45, doi:10.1097/SMJ.0b013e3181fd7d5a (2011).
787	60	Navon-Venezia, S., Kondratyeva, K. & Carattoli, A. Klebsiella pneumoniae: a major
788		worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 41, 252-275,
789		doi:10.1093/femsre/fux013 (2017).
790	61	Cohen, S. H. et al. Clinical practice guidelines for Clostridium difficile infection in
791		adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and
792		the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31,
793		431-455, doi:10.1086/651706 (2010).
794	62	Pollock, N. R. et al. Comparison of Clostridioides difficile Stool Toxin Concentrations in
795		Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive
796		Quantitative Immunoassay. Clin Infect Dis 68, 78-86, doi:10.1093/cid/ciy415 (2019).
797	63	Crobach, M. J. T. et al. Understanding Clostridium difficile Colonization. Clin Microbiol
798		<i>Rev</i> <b>31</b> , doi:10.1128/CMR.00021-17 (2018).
799	64	Antharam, V. C. et al. An Integrated Metabolomic and Microbiome Analysis Identified
800		Specific Gut Microbiota Associated with Fecal Cholesterol and Coprostanol in
801		Clostridium difficile Infection. PLoS One 11, e0148824,
802		doi:10.1371/journal.pone.0148824 (2016).
803	65	Khanna, S. et al. Gut microbiome predictors of treatment response and recurrence in
804		primary Clostridium difficile infection. Aliment Pharmacol Ther 44, 715-727,
805		doi:10.1111/apt.13750 (2016).

806	66	Han, S. H., Yi, J., Kim, J. H., Lee, S. & Moon, H. W. Composition of gut microbiota in
807		patients with toxigenic Clostridioides (Clostridium) difficile: Comparison between
808		subgroups according to clinical criteria and toxin gene load. <i>PLoS One</i> 14, e0212626,
809		doi:10.1371/journal.pone.0212626 (2019).
810	67	Daquigan, N., Seekatz, A. M., Greathouse, K. L., Young, V. B. & White, J. R. High-
811		resolution profiling of the gut microbiome reveals the extent of Clostridium difficile
812		burden. <i>NPJ Biofilms Microbiomes</i> <b>3</b> , 35, doi:10.1038/s41522-017-0043-0 (2017).
813	68	Hudson, L. E., Anderson, S. E., Corbett, A. H. & Lamb, T. J. Gleaning Insights from
814		Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of
815		Combination Microbial Therapies. <i>Clin Microbiol Rev</i> <b>30</b> , 191-231,
816		doi:10.1128/CMR.00049-16 (2017).
817	69	Fujitani, S., George, W. L., Morgan, M. A., Nichols, S. & Murthy, A. R. Implications for
818		vancomycin-resistant Enterococcus colonization associated with Clostridium difficile
819		infections. Am J Infect Control <b>39</b> , 188-193, doi:10.1016/j.ajic.2010.10.024 (2011).
820	70	Antharam, V. C. et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in
821		Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 51, 2884-2892,
822		doi:10.1128/JCM.00845-13 (2013).
823	71	Sokol, H. et al. Specificities of the intestinal microbiota in patients with inflammatory
824		bowel disease and Clostridium difficile infection. Gut Microbes 9, 55-60,
825		doi:10.1080/19490976.2017.1361092 (2018).
826	72	Mezzatesta, M. L., Gona, F. & Stefani, S. Enterobacter cloacae complex: clinical impact
827		and emerging antibiotic resistance. Future Microbiol 7, 887-902, doi:10.2217/fmb.12.61
828		(2012).
829	73	Umana, A. et al. Utilizing Whole Fusobacterium Genomes To Identify, Correct, and
830		Characterize Potential Virulence Protein Families. J Bacteriol 201,
831		doi:10.1128/JB.00273-19 (2019).
832	74	Deng, H. Interpreting tree ensembles with inTrees. International Journal of Data Science
833		and Analytics 7, 277-287, doi:10.1007/s41060-018-0144-8 (2019).
834	75	Dreiseitl, S. & Ohno-Machado, L. Logistic regression and artificial neural network
835		classification models: a methodology review. J Biomed Inform 35, 352-359,
836		doi:10.1016/s1532-0464(03)00034-0 (2002).
837	76	Tollenaar, N. & van der Heijden, P. G. M. Optimizing predictive performance of criminal
838		recidivism models using registration data with binary and survival outcomes. PLoS One
839		14, e0213245, doi:10.1371/journal.pone.0213245 (2019).
840	77	Norton, E. C. & Dowd, B. E. Log Odds and the Interpretation of Logit Models. Health
841		Serv Res 53, 859-878, doi:10.1111/1475-6773.12712 (2018).
842	78	Liu, K. H. & Xu, C. G. A genetic programming-based approach to the classification of
843		multiclass microarray datasets. Bioinformatics 25, 331-337,
844		doi:10.1093/bioinformatics/btn644 (2009).
845	79	Fadrosh, D. W. et al. An improved dual-indexing approach for multiplexed 16S rRNA
846		gene sequencing on the Illumina MiSeq platform. Microbiome 2, 6, doi:10.1186/2049-
847		2618-2-6 (2014).
848	80	Biesheuvel, C. J., Siccama, I., Grobbee, D. E. & Moons, K. G. Genetic programming
849		outperformed multivariable logistic regression in diagnosing pulmonary embolism. J Clin
850		Epidemiol 57, 551-560, doi:10.1016/j.jclinepi.2003.10.011 (2004).

Staats, K., Pantridge, E., Cavaglia, M., Milovanov, I. & Anivan, A. TensorFlow Enabled Genetic Programming. arXiv e-prints, arXiv:1708.03157 (2017). Acknowledgements: The authors thank all patients who participated in this study, as well as Carolyn Alonso, Javier Villafuerte Gálvez, and the technologists in the Beth Israel Deaconess Medical Center Clinical Microbiology Laboratory for their help with sample collection. The authors thank Zheng Sun for valuable discussion on the microbiome data analysis. Funding: Y.-Y.L. acknowledged grants from National Institutes of Health (R01AI141529, R01HD093761, UH3OD023268, U19AI095219 and U01HL089856). N.R.P. and C.P.K. acknowledged grants from National Institutes of Health (R01AI116596) and Institut Mérieux. S.K. was supported by the China Scholarship Council. Author contributions: Y.-Y.L, N.R.P., X.C., and C.P.K. conceived and designed the project. C.P.K., N.R.P., X.C. and K.D. performed the clinical study. X.C., H.X., and Q.L. contributed to the serum immune marker measurement. K.W.G. and A.J.G. performed fecal DNA extraction and bacterial 16S rRNA sequencing. S.K., X.-W.W., and Y.-Y.L. performed all the data analysis and wrote the manuscript. N.R.P., K.W.G., C.P.K., and K.D. edited the manuscript. **Competing interests:** C.P.K. has acted as a paid consultant to Artugen, Facile Therapeutics, First Light Biosciences, Finch, Matrivax, Merck, Seres Health, and Vedanta and has received grant support from Merck. X. C. has acted as a paid consultant to Artugen. All other authors report no potential conflicts of interest. Data and materials availability: Data will be available from corresponding authors upon reasonable request. 





Fig. 1. Comparing the alpha diversity of the gut microbiota of subjects with different *C*.

898 difficile infection/colonization statuses (Control, Non-CDI Diarrhea, Asymptomatic

899 Carriage, and CDI) using different alpha diversity measures. (A) Taxa richness. (B) Chao1.

900 (C) Evenness. (D) Shannon index. Each dot represents the alpha diversity value of a particular

- 901 subject's gut microbiota. Statistical significance was determined by Mann–Whitney test, 902 \*P < 0.05.
- 903



904

Fig. 2. Ordination analysis and beta diversity comparison of the gut microbiota (and host
 immune markers) for subjects with different *C. difficile* infection/colonization statuses

907 (Control, Non-CDI Diarrhea, Asymptomatic Carriage, and CDI). (A) Principal Coordinates

908 Analysis (PCoA) plot based on Bray–Curtis dissimilarities of microbial compositions. (B)

909 Boxplot of the gut microbiome Bray–Curtis dissimilarity between subjects within each group.

910 (C) Principle component analysis (PCA) plot of host immune marker concentrations. (D)

- 911 Boxplot of the Euclidean distance for the host immune markers of subjects within each group.
- 912 Statistical significance was determined by Mann–Whitney test, \*P < 0.05, \*\*P < 0.01,
- **913** \*\*\**P* < 0.001.
- 914



915

916 Fig. 3. Relative abundances of differentially abundant genera identified by ANCOM in

917 comparing different groups. (A) CDI vs. Asymptomatic Carriage. (B) CDI vs. Non-CDI

- 918 Diarrhea. (C) CDI vs. Non-CDI. The top differentially abundant taxa were ranked based on their
- 919 W statistics (from left to right). The relative abundance (%) are plotted on log10 scale. The
- 920 notches in the boxplots show the 95% confidence interval around the median.
- 921
- 922



923

924 Fig. 4. Microbial correlation networks of different groups. (A) Control. (B) Non-CDI

925 Diarrhea. (C) Asymptomatic Carriage. (D) CDI. Nodes represent genera and are colored based

926 on their phylum. Edges represent microbial correlations: green/red means positive/negative

- 927 correlations, respectively. Edge thickness indicates correlation strength, and only the high-
- 928 confidence interactions (*p*-value < 0.05) with high absolute correlation coefficients (> 0.3) were 929
- presented. For each group, we further identified the top-three most connected genera/nodes.
- They are *Ruminococcus* 1, *Roseburia* and *Lachnospiraceae* UCG-008 for the Control group, 930
- [Ruminococcus] torques group, [Eubacterium] hallii group and Blautia for the Non-CDI 931
- 932 Diarrhea group, Ruminiclostridium 5, Enterococcus and Lachnospiraceae UCG 008 for the
- 933 Asymptomatic Carriage group, and Alistipes, Ruminiclostridium 5 and Lachnoclostridium for 934 the CDI group.
- 26



936 Fig. 5. Correlations between gut microbial abundances and host immune markers in

- 937 different groups, quantified by Spearman correlation with Benjamini-Hochberg correction.
- 938 (A) Control. (B) Non-CDI Diarrhea. (C) Asymptomatic Carriage. (D) CDI. Rows represent
- 939 genera; columns represent immune markers. The layout of the heatmap is followed the
- 940 hierarchical clustering results of Control cohort (see Fig.S4). Red/blue represents
- 941 positive/negative correlation, respectively. The intensity of the colors denotes the strength of the
- 942 correlation.  $*\alpha < 0.05$ ,  $**\alpha < 0.01$ ,  $***\alpha < 0.001$ .
- 943
- 944

medRxiv preprint doi: https://doi.org/10.1101/2020.04.27.20081653; this version posted May 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



946 Fig. 6. The performance of RF-based classification models based on various types of

947 features in differentiating CDI from other groups. (A) CDI vs. Asymptomatic Carriage. (B)
948 CDI vs. Non-CDI Diarrhea. (C) CDI vs. Non-CDI. For each classification task, we used different

types of features: (1) the top-1 immune marker feature (based on mean decrease accuracy); (2)

950 the top-1 genus feature; (3) all immune markers; (4) all genera; (5) integration of all immune

951 markers and genera; (6) selected features from the set of all immune markers and genera. Error

- bars represent the standard errors of the means (SEM).

	NAAT negativ	ve	NAAT positive		
Charactoristics	Control	Non-CDI	Asymptomatic	CDI(n=112)	
Character istics	(n=47)	Diarrhea (n=44)	Carriage (n=40)	CDI (II-112)	
Sex					
Female	14 (29.79%)	22 (50.00%)	20 (50.00%)	61 (54.46%)	
Male	33 (70.21%)	22 (50.00%)	20 (50.00%)	51 (45.54%)	
Age, Avg $\pm$ SD	$62.40 \pm 12.33$	$63.07 \pm 13.15$	$62.15 \pm 17.25$	$64.99 \pm 15.62$	
Ethnicity					
Hispanic	1 (2.13%)	3 (6.82%)	1 (2.50%)	6 (5.36%)	
Non-Hispanic	38 (80.85%)	37 (84.09%)	31 (77.50%)	96 (85.71%)	
Unknown	8 (17.02%)	4 (9.09%)	8 (20.00%)	10 (8.93%)	
Race					
White	33 (70.21%)	28 (63.64%)	28 (70.00%)	89 (79.46%)	
Other	4 (8.51%)	10 (22.73%)	3 (7.50%)	23 (20.54%)	
Unknown	10 (21.28%)	6 (13.64%)	9 (22.50%)	0 (0.00%)	

# 972 Table 1. Demographic characteristics of the enrolled subjects.

## 997 Table 2. Diagnostic scores derived from symbolic classification (SC) and logistic regression

- 998 (LR). For each subject *i*, we calculate his/her diagnostic score f(i) (or p(i)) based on one of the
- following formulas derived from SC (or LR), respectively. For SC, the class of subject *i* is CDI
- 1000 if f(i) > 0; or Asymptomatic Carriage (or Non-CDI Diarrhea, Non-CDI) if  $f(i) \le 0$ . For LR,
- 1001 the class of subject *i* is CDI if  $p(i) \ge 0.5$ ; or Asymptomatic Carriage (or Non-CDI Diarrhea,
- 1002 Non-CDI) if p(i) < 0.5. Here, both f(i) and p(i) were learned from the entire dataset. Features
- 1003 used here include:  $x_1$ : GCSF;  $x_2$ : IgA\_toxA;  $x_3$ : IgA\_toxB;  $x_4$ : IL6;  $x_5$ : TNF $\alpha$ ;  $x_6$ :
- **1004** *Anaerobacillus*;  $x_7$ : *Curvibacter*;  $x_8$ : *Enterobacter*;  $x_9$ : *Enterococcus*;  $x_{10}$ : *Epulopiscium*;  $x_{11}$ :
- 1005 [Eubacterium]\_haillii\_group;  $x_{12}$ : Fusobacterium;  $x_{13}$ : Moryella;  $x_{14}$ : Stenotrophomonas;  $x_{15}$ :
- 1006 Veillonella. In particular, for each classification task (regardless of using SC or LR), the
- 1007 following selected features were: (1) CDI vs. Asymptomatic Carriage:  $x_1$ ,  $x_4$ ,  $x_{13}$  and  $x_{15}$ ; (2)
- 1008 CDI vs. Non-CDI Diarrhea:  $x_1$ ,  $x_2$ ,  $x_9$ ,  $x_{10}$ , and  $x_{11}$ ; (3) CDI vs. Non-CDI:  $x_1$ ,  $x_3$ ,  $x_4$ ,  $x_5$ ,  $x_6$ ,  $x_7$ ,
- 1009  $x_8, x_{12}, x_{14}$  and  $x_{15}$ . Note that in the calculation of precision, recall and F1-score, we can treat
- 1010 either CDI (or Asymptomatic Carriage, Non-CDI Diarrhea, Non-CDI) as the true positive.
- 1011 Results shown in the parenthesis represent the latter case.
- 1012

Model	Diagnostic	Formula	Accur	Precision	Recall	F1-
			acy			score
Model SC	CDI vs. Asymptomatic Carriage	$f(i) = x_1 * x_{15}(x_1^3 - 0.2 * x_{13} + 0.4) + 1.1 * x_1 - 0.1$ * x <sub>4</sub> - 18.25	0.896	0.914 (0.840)	0.949 (0.75)	0.931 (0.792)
	CDI vs. Non- CDI Diarrhea	$f(i) = x_9 * x_2(0.5 * x_{10} - 1) + x_{11}(0.02 * x_{11} - x_1) + x_2 \left(1 - \frac{10}{x_1}\right) - \frac{0.003}{x_9}$	0.900	0.946 (0.826)	0.897 (0.905)	0.921 (0.864)
	CDI vs. Non- CDI	$f(i) = x_1 * x_3(0.2 * x_1 * x_5 * x_6 * x_{14} + 0.04 * x_1 * x_7 + 0.3 * x_1 * x_{15} * x_8^4 + x_1 + x_{12}(0.5 * x_7 + x_1 * x_{14}) + x_7(0.1 * x_4 - x_6) + x_{14}(x_{14} - 2)$	0.882	0.889 (0.878)	0.821 (0.927)	0.853 (0.902)
	CDI vs. Asymptomatic Carriage	$\log\left(\frac{p(i)}{1-p(i)}\right) = 0.66725 - 0.04442 * x_1 + 0.01022 * x_4 + 7.51484 * x_{13} - 85.00213 * x_{15}$	0.830	0.895 (0.667)	0.872 (0.714)	0.883 (0.690)
LR	CDI vs. Non- CDI Diarrhea	$\log\left(\frac{p(i)}{1-p(i)}\right) = 0.01974 - 0.002084 * x_1 - 0.02391$ $* x_2 + 1.895 * x_9 - 12740 * x_{10}$ $+ 163.9 * x_{11}$	0.800	0.814 (0.765)	0.897 (0.619)	0.854 (0.684)
	CDI vs. Non- CDI	$\log\left(\frac{p(i)}{1-p(i)}\right) = 2.122 - 0.01002 * x_1 + 0.01833 * x_3$ $- 0.006334 * x_4 - 0.009566 * x_5$ $- 4609 * x_6 - 8576 * x_7 - 40.75 * x_8$ $- 101.1 * x_{12} + 32.84 * x_{14} - 43.4$ $* x_{15}$	0.813	0.841 (0.798)	0.679 (0.908)	0.752 (0.850)

1013

1014

# 1016 Supplementary Materials

- 1017
- 1018 Fig. S1. The "driver" taxa responsible for the change of microbial correlations between CDI and
- 1019 Asymptomatic Carriage
- 1020 Fig. S2. The "driver" taxa responsible for the change of microbial correlations between CDI and
- 1021 Non-CDI Diarrhea.
- Fig. S3. The "driver" taxa responsible for the change of microbial correlations between CDI andNon-CDI.
- Fig. S4. Significant correlations between gut microbial abundances and host immune markers inthe Control group.
- Fig. S5. Gut microbiota and host immune markers can accurately differentiate different groups inmulti-class classification models.
- 1028 Fig. S6. Using the mean decrease accuracy (MDA) ranking and the 1-SE rule to select features to
- 1029 distinguish CDI from other groups.
- 1030 Fig. S7. The fitness evolution during the genetic programming.
- 1031 Table S1. Sample sizes of different data types in different groups.
- 1032 Table S2. Permutational multivariate analysis of variance (PERMANOVA) in microbial
- 1033 compositions and immune markers.
- 1034 Table S3. Differentially abundant genera between CDI and Asymptomatic Carriage groups
- 1035 detected by ANCOM, adjusted for age and sex.
- 1036 Table S4. Differentially abundant genera between CDI and Non-CDI Diarrhea groups detected
- 1037 by ANCOM, adjusted for age and sex.
- 1038 Table S5. Differentially abundant genera between CDI and Non-CDI groups detected by
- 1039 ANCOM, adjusted for age and sex.
- 1040 Table S6. Characteristics of microbial correlation networks associated with different groups.
- 1041 Table S7. Comparison of host immune markers in different groups.
- 1042 Table S8. Accuracy, Precision, Recall and F1-score of symbolic classification in CDI diagnosis.
- 1043
- 1044
- 1045
- 1046
- 1047



1048

1049 Fig. S1. The "driver" taxa responsible for the change of microbial correlations between

1050 CDI and Asymptomatic Carriage. Node sizes are proportional to their scaled neighbor shift

- 1051 (NESH) score (i.e., a score identifying important microbial taxa of microbial association
- networks) and a node is colored red if its betweenness increases when comparing microbial
- 1053 correlation networks of CDI with that of Asymptomatic Carriage. All taxa belonging to same
- 1054 community (common sub-network) are randomly assigned a color to their labels. Red (or green)
- edges represent microbial correlations that are only present in the CDI (or Asymptomatic
- 1056 Carriage) network, respectively. Blue edges present common microbial correlations that are
- 1057 present in both networks.



1058

1059 Fig. S2. The "driver" taxa responsible for the change of microbial correlations between

1060 CDI and Non-CDI Diarrhea. Node sizes are proportional to their scaled NESH score and a

1061 node is colored red if its betweenness increases when comparing microbial correlation networks

- of CDI with that of Non-CDI Diarrhea. All taxa belonging to same community (common sub network) are randomly assigned a color to their labels. Red (or green) edges represent microbial
- 1064 correlations that are only present in the CDI (or Non-CDI Diarrhea) network, respectively. Blue
- 1065 edges present common microbial correlations that are present in both networks.
- 1066
- 1067



1068

1069 Fig. S3. The potential "driver taxa" responsible for the change of microbial correlations

between CDI and Non-CDI. Node sizes are proportional to their scaled NESH score and a node
is colored red if its betweenness increases when comparing microbial correlation networks of
CDI with that of Non-CDI. All taxa belonging to same community (common sub-network) are
randomly assigned a color to their labels. Red (or green) edges represent microbial correlations
that are only present in the CDI (or Non-CDI) network, respectively. Blue edges present

- 1075 common microbial correlations that are present in both networks.
- 1076
- 1077
- 1078





1080 Fig. S4. Significant correlations between gut microbial abundances and host immune

markers in the Control group. Gut microbial compositions and host immune markers were
 clustered through hierarchical clustering. Rows correspond to bacterial taxa at genus level;
 columns correspond to host immune markers. Red/blue represents positive/negative association,
 respectively. The intensity of the colors denotes the strength of correlation between the genus
 abundance and the immunological expression level.



## 

1094 Fig. S5. Gut microbiota and host immune markers can accurately differentiate different

1095 groups in multi-class classification models. (A) Use host immune markers alone. (B) Use gut

1096 microbiota data (at genus level) alone. (C) The integration of host immune markers and

1097 microbial data. The performance of each classifier is measured by the macro-average and micro-1098 average AUCs.



- 1107
- 1108

1109 Fig. S6. Using the mean decrease accuracy (MDA) ranking and the 1-SE rule to select

1110 features to distinguish CDI from other groups. The most important features of cytokine data,

1111 microbiome data, and the integration of cytokines and microbiome data in classifying CDI vs.

1112 Asymptomatic Carriage (A, B and G), CDI vs. Non-CDI Diarrhea (C, D and H) and CDI vs.

- 1113 Non-CDI (E, F and I). The performance of classifiers using different sets of integrated features:
- selected based on MDA or randomly selected in CDI vs Asymptomatic Carriage (J), CDI vs
- 1115 Non-CDI Diarrhea (K) and CDI vs Non-CDI (L). The minimum set of features selected based on
- the MDA ranking and the 1-SE rule is highlighted by a vertical blue dashed line. Error bars
- 1117 represent the standard errors of the means (SEM).
- 1118
- 1119
- 1120
- 1121







**programming.** The fitness function is a maximization function, and the tree with highest fitness score in each iteration were plotted. The final selected number of generations is highlighted with a vertical blue dashed line.

# 1139 Table S1. Sample sizes of different data types in different groups.

	NAAT ne	egative	NAAT positive		tive		
Characteristics	Control	Non-CDI	Asymptomatic	CDI	Total		
		Diarrhea	Carriage				
Immunological data	45	44	35	99	223		
Microbial data	41	42	33	91	207		
Immunological & microbial data	39	42	28	/8	187		

#### 1173 Table S2. Permutational multivariate analysis of variance (PERMANOVA) in microbial

1174 compositions and immune markers. CDI statuses: Control, Non-CDI Diarrhea, Asymptomatic

1175 Carriage, and CDI. Race: White, Native American, Asian, African American, Pacific Islander

and mixed origin. Ethnicity: Hispanic and Not Hispanic. Here F represents the F-statistic: a

1177 larger F value indicate that the between-group variation is greater than within-group variation.  $R^2$ 

represents the variation explained by the model. P represents the *P*-value calculated from

1179 permutation.

	Microbio	ome		Cytokines			
Test factors	F	R <sup>2</sup>	Р	F	R <sup>2</sup>	Р	
CDI status	2.285	0.0388	0.001	3.351	0.052	0.016	
Age	1.605	0.009	0.081	0.541	0.003	0.516	
Sex	1.557	0.009	0.095	0.916	0.005	0.372	
Race	0.881	0.031	0.832	1.595	0.050	0.153	
Ethnicity	0.476	0.003	0.961	0.206	0.001	0.771	

#### 1207 Table S3. Differentially abundant genera between CDI and Asymptomatic Carriage groups

#### 1208 detected by ANCOM, adjusted for age and sex. For each genus, the first column represents its

- 1209 W statistic, and subsequent four columns represent logical indicators of whether it is
- 1210 differentially abundant under a series of cutoffs (0.9, 0.8, 0.7 and 0.6). The last two columns
- 1211 represent its relative abundance (mean  $\pm$  standard deviation) in the two groups.

Genera	W_stat	Cutoff 0.9	Cutoff 0.8	Cutoff 0.7	Cutoff 0.6	Relative abundance (%) in CDI	Relative abundance (%) in Asymptomatic Carriage
Veillonella	204	TRUE	TRUE	TRUE	TRUE	$1.86\pm5.55$	$0.06 \pm 0.20$
Enterobacter	182	FALSE	TRUE	TRUE	TRUE	$0.79 \pm 1.81$	$0.20 \pm 1.01$
Lactococcus	179	FALSE	TRUE	TRUE	TRUE	$0.10\pm0.30$	$0.36\pm0.69$
Dorea	177	FALSE	TRUE	TRUE	TRUE	$0.10\pm0.26$	$0.79\pm2.00$
Moryella	174	FALSE	TRUE	TRUE	TRUE	$0.20\pm1.19$	$0.13\pm0.24$
[Ruminococcus]_gauvreauii_group	173	FALSE	TRUE	TRUE	TRUE	$0.09\pm0.26$	1.10± 3.68
Stenotrophomonas	167	FALSE	TRUE	TRUE	TRUE	$0.13\pm0.79$	$0.28\pm0.76$
Agathobacter	158	FALSE	FALSE	TRUE	TRUE	$0.07\pm0.19$	$0.25 \pm 0.42$
Granulicatella	157	FALSE	FALSE	TRUE	TRUE	$0.31\pm1.10$	$0.10\pm0.46$
Blautia	154	FALSE	FALSE	TRUE	TRUE	$5.30\pm7.99$	$10.18\pm14.05$
Sellimonas	150	FALSE	FALSE	TRUE	TRUE	$0.46\pm2.18$	$1.20 \pm 2.50$
Eggerthella	147	FALSE	FALSE	TRUE	TRUE	$1.39\pm2.16$	$2.98 \pm 4.06$
Faecalitalea	145	FALSE	FALSE	TRUE	TRUE	$0.91 \pm 2.07$	$1.41 \pm 3.05$
Dialister	141	FALSE	FALSE	FALSE	TRUE	$1.10 \pm 7.07$	$0.23 \pm 1.27$
Lachnospiraceae_UCG_008	135	FALSE	FALSE	FALSE	TRUE	$0.20 \pm 0.39$	$0.37 \pm 0.45$

#### 1230 Table S4. Differentially abundant genera between CDI and Non-CDI Diarrhea groups

1231 detected by ANCOM, adjusted for age and sex. For each genus, the first column represents its

- 1232 W statistic, and subsequent four columns represent logical indicators of whether it is
- 1233 differentially abundant under a series of cutoffs (0.9, 0.8, 0.7 and 0.6). The last two columns
- 1234 represent its relative abundance (mean  $\pm$  standard deviation) in the two groups.

Genera	W_stat	detected_0.9	detected_0.8	detected_0.7	detected_0.6	Relative abundance (%) in CDI	Relative abundance (%) in Non- CDI Diarrhea
Clostridioides	206	TRUE	TRUE	TRUE	TRUE	$0.67 \pm 1.80$	$0.03\pm0.16$
[Eubacterium]_hallii_group	199	TRUE	TRUE	TRUE	TRUE	$0.40 \pm 2.12$	$1.14\pm2.05$
Collinsella	195	TRUE	TRUE	TRUE	TRUE	$0.57 \pm 1.59$	$2.57\pm5.33$
Enterobacter	189	TRUE	TRUE	TRUE	TRUE	$0.79 \pm 1.81$	$0.05\pm0.20$
Epulopiscium	166	FALSE	TRUE	TRUE	TRUE	$0.06\pm0.30$	$0.00\pm0.01$
Agathobacter	165	FALSE	TRUE	TRUE	TRUE	$0.07\pm0.19$	$0.42\pm0.93$
Dorea	165	FALSE	TRUE	TRUE	TRUE	$0.10\pm0.26$	$0.96\pm2.24$
Escherichia_Shigella	163	FALSE	FALSE	TRUE	TRUE	$3.54 \pm 6.46$	$1.84\pm5.01$
Eisenbergiella	149	FALSE	FALSE	TRUE	TRUE	$1.03\pm3.36$	$0.10\pm0.40$
Stenotrophomonas	147	FALSE	FALSE	TRUE	TRUE	$0.13\pm0.79$	$0.09\pm0.17$
Streptococcus	147	FALSE	FALSE	TRUE	TRUE	$6.16 \pm 13.27$	$7.00\pm7.39$
Dialister	138	FALSE	FALSE	FALSE	TRUE	$1.10\pm7.07$	$0.06\pm0.25$
Ruminiclostridium	137	FALSE	FALSE	FALSE	TRUE	$0.08\pm0.44$	$0.00\pm0.01$
Fusobacterium	131	FALSE	FALSE	FALSE	TRUE	$0.18\pm0.51$	$0.01\pm0.04$
Klebsiella	131	FALSE	FALSE	FALSE	TRUE	$1.75 \pm 6.94$	$0.58\pm2.74$
Veillonella	125	FALSE	FALSE	FALSE	TRUE	$1.86 \pm 5.55$	$0.27\pm0.78$

#### 1252 Table S5. Differentially abundant genera between CDI and Non-CDI groups detected by

1253 ANCOM, adjusted for age and sex. For each genus, the first column represents its W statistic,

1254 and subsequent four columns represent logical indicators of whether it is differentially abundant

under a series of cutoffs (0.9, 0.8, 0.7 and 0.6). The last two columns represent its relative

1256 abundance (mean  $\pm$  standard deviation) in the two groups.

		detected	detected_	detected_	detected_	Relative	Relative
Genera	W_stat					abundance	abundance (%)
		_0.9	0.0	0.7	0.0	(%) in CDI	in Non-CDI
Clostridioides	201	TRUE	TRUE	TRUE	TRUE	$0.67 \pm 1.81$	$0.08\pm0.26$
Veillonella	201	TRUE	TRUE	TRUE	TRUE	$1.86\pm5.58$	$0.14\pm0.50$
Enterobacter	200	TRUE	TRUE	TRUE	TRUE	$0.79 \pm 1.82$	$0.08\pm0.55$
Klebsiella	196	TRUE	TRUE	TRUE	TRUE	$1.75\pm6.98$	$0.49\pm2.25$
Collinsella	194	TRUE	TRUE	TRUE	TRUE	$0.57 \pm 1.60$	$2.29 \pm 4.64$
Fusobacterium	194	TRUE	TRUE	TRUE	TRUE	$0.18\pm0.51$	$0.04\pm0.25$
[Eubacterium]_hallii_group	193	TRUE	TRUE	TRUE	TRUE	$0.40\pm2.13$	$1.21\pm2.55$
Stenotrophomonas	193	TRUE	TRUE	TRUE	TRUE	$0.13\pm0.79$	$0.30\pm1.06$
Escherichia_Shigella	191	TRUE	TRUE	TRUE	TRUE	$3.54\pm6.50$	$1.96\pm5.31$
[Ruminococcus]_gnavus_group	185	FALSE	TRUE	TRUE	TRUE	$1.73\pm3.15$	$0.50 \pm 1.81$
Agathobacter	179	FALSE	TRUE	TRUE	TRUE	$0.07\pm0.19$	$0.50\pm1.37$
Dialister	176	FALSE	TRUE	TRUE	TRUE	$1.10\pm7.11$	$0.10\pm0.69$
Dorea	170	FALSE	TRUE	TRUE	TRUE	$0.10\pm0.26$	$0.86 \pm 2.17$
Lactococcus	169	FALSE	TRUE	TRUE	TRUE	$0.10\pm0.30$	$0.23\pm0.56$
Anaerobacillus	164	FALSE	FALSE	TRUE	TRUE	$0.02\pm0.06$	$0.00\pm0.01$
Moryella	164	FALSE	FALSE	TRUE	TRUE	$0.20\pm1.19$	$0.11\pm0.26$
Adlercreutzia	162	FALSE	FALSE	TRUE	TRUE	$0.00\pm0.02$	$0.08\pm0.33$
Family_XIII_AD3011_group	161	FALSE	FALSE	TRUE	TRUE	$0.03\pm0.07$	$0.09\pm0.16$
Erysipelatoclostridium	160	FALSE	FALSE	TRUE	TRUE	$3.56\pm7.56$	$0.80 \pm 1.79$
[Eubacterium]_brachy_group	154	FALSE	FALSE	TRUE	TRUE	$0.01\pm0.03$	$0.04\pm0.10$
Campylobacter	154	FALSE	FALSE	TRUE	TRUE	$0.03\pm0.11$	$0.00\pm0.00$
Citrobacter	154	FALSE	FALSE	TRUE	TRUE	$0.41 \pm 2.11$	$0.20\pm1.09$
Clostridium_sensu_stricto_1	151	FALSE	FALSE	TRUE	TRUE	$0.72\pm1.76$	$0.38 \pm 1.19$
Clostridium_sensu_stricto_13	151	FALSE	FALSE	TRUE	TRUE	$0.07\pm0.41$	$0.00\pm0.01$
Akkermansia	149	FALSE	FALSE	TRUE	TRUE	$3.3\pm9.68$	$6.41 \pm 12.03$
Alistipes	142	FALSE	FALSE	FALSE	TRUE	$1.28\pm3.05$	$1.30\pm2.34$
Bacillus	139	FALSE	FALSE	FALSE	TRUE	$0.01\pm0.03$	$0.00\pm0.01$
Enterorhabdus	137	FALSE	FALSE	FALSE	TRUE	$0.01\pm0.03$	$0.08\pm0.55$
Pantoea	137	FALSE	FALSE	FALSE	TRUE	$0.01\pm0.03$	$0.00\pm0.00$
Ruminococcaceae_UCG_004	134	FALSE	FALSE	FALSE	TRUE	$0.05\pm0.17$	$0.15\pm0.41$
Curvibacter	132	FALSE	FALSE	FALSE	TRUE	$0.01\pm0.01$	$0.00\pm0.00$
Granulicatella	131	FALSE	FALSE	FALSE	TRUE	$0.31 \pm 1.11$	$0.08\pm0.27$
Lachnospiraceae_NC2004_group	131	FALSE	FALSE	FALSE	TRUE	$0.02\pm0.04$	$0.05\pm0.09$
Ruminiclostridium_5	131	FALSE	FALSE	FALSE	TRUE	$0.50 \pm 1.11$	$1.33\pm2.79$
Epulopiscium	130	FALSE	FALSE	FALSE	TRUE	$0.06\pm0.30$	$0.01\pm0.04$
Robinsoniella	130	FALSE	FALSE	FALSE	TRUE	$0.06\pm0.33$	$0.01\pm0.07$
[Eubacterium]_coprostanoligenes_group	128	FALSE	FALSE	FALSE	TRUE	$0.13\pm0.39$	$0.39\pm2.19$
Eggerthella	128	FALSE	FALSE	FALSE	TRUE	$1.39\pm2.17$	$1.86\pm2.96$
Erwinia	126	FALSE	FALSE	FALSE	TRUE	$0.00\pm0.00$	$0.00\pm0.00$
[Ruminococcus]_gauvreauii_group	124	FALSE	FALSE	FALSE	TRUE	$0.09\pm0.26$	$0.45\pm2.04$

-

**1** 

#### 1257 Table S6. Characteristics of microbial correlation networks associated with different

1

## 1258

Г

groups.

\_\_\_\_\_

1259

	Groups	Average degree	Clustering	Edges	Graph density	Modularity	Nodes
	Control	9.475	0.368	938	0.048	0.377	198
	Non-CDI Diarrhea	11.314	0.474	1171	0.055	0.271	207
	Asymptomatic Carriage	9.730	0.349	973	0.049	0.442	200
	CDI	5.200	0.502	299	0.046	0.568	115
1260		1				I	
1261							
1262							
1263							
1264							
1265							
1266							
1267							
1268							
1269							
1270							
1271							
1272							
1273							
1274							
1275							
1276							
1277							
1278							
1279							
1280							
1281							
1282							
1283							
1284							
1285							
1286							
1287							
1288							
1289							
1290							
1791							

\_

## Table S7. Comparison of host immune markers in different groups. Mean (Q1, Q3); p-value

- 1293 calculated with Mann-Whitney U test.

Immune markers	Control (n=45)	Non-CDI Diarrhea (n=44)	Asymptomatic Carriage (n=35)	CDI (n=99)	P-value (CDI vs. Asymptomatic Carriage)	P-value (CDI vs. Non-CDI Diarrhea)	P-value (CDI vs. Non-CDI)
IgA_toxA	33.63 (7.24, 62.54)	16.94 (8.44, 16.96)	44.59 (10.21, 102.50)	48.41 (12.10, 104)	0.543	< 0.001	0.001
IgG_toxA	19.87 (9.75, 22.43)	24.20 (11.11, 27.77)	22.20 (11.48, 24.86)	40.09 (14.77, 59.18)	0.009	0.002	< 0.001
IgM_toxA	2.04 (0.00, 2.87)	2.45 (0.00, 3.36)	2.15 (0.00, 2.98)	2.09 (0.00, 2.84)	0.316	0.643	0.172
IgA_toxB	9.73 (2.68, 8.61)	18.78 (4.07, 19.18)	23.02 (5.80, 20.12)	35.07 (4.76, 67.79)	0.469	0.102	0.002
IgG_toxB	9.66 (4.30, 9.80)	11.97 (5.92, 13.46)	13.57 (3.98, 15.98)	14.61 (4.92, 17.56)	0.980	0.870	0.379
IgM_toxB	12.12 (2.28, 9.24)	13.72 (2.78, 12.77)	11.08 (2.74, 9.04)	14.99 (1.87, 10.47)	0.261	0.192	0.256
GCSF	11.27 (0.46, 14.17)	49.37 (2.18, 29.36)	20.01 (2.18, 20.49)	386.64 (22.56, 159.95)	< 0.001	< 0.001	< 0.001
IL-10	8.29 (0.00, 3.15)	33.22 (0.00, 14.06)	9.05 (0.00, 9.78)	35.17 (1.63, 27.99)	0.002	0.021	< 0.001
IL-13	1.38 (0.00, 0.00)	1.97 (0.00, 0.34)	5.22 (0.00, 0.00)	9.35 (0.00, 1.09)	0.529	0.593	0.167
IL-15	1.56 (0.00, 0.24)	2.82 (0.00, 3.28)	2.03 (0.00, 1.46)	5.22 (0.19, 5.33)	0.007	0.037	< 0.001
IL-1b	0.05 (0.00, 0.00)	0.11 (0.00, 0.00)	0.44 (0.00, 0.00)	0.7 (0.00, 0.00)	0.920	0.387	0.159
IL-2	0.04 (0.00, 0.00)	0.05 (0.00, 0.00)	0.45 (0.00, 0.00)	1.4 (0.00, 0.00)	0.630	0.151	0.051
IL-4	1.88 (0.00, 0.00)	9.58 (2.57, 12.44)	5.73 (0.00, 0.00)	11.54 (0.00, 9.12)	0.002	0.011	0.032
IL-6	15.78 (0.00, 3.77)	24.97 (0.00, 10.71)	9.52 (0.00, 5.46)	47.09 (2.52, 37.71)	< 0.001	< 0.001	< 0.001
IL-8	100.51 (12.37, 59.19)	80.85 (15.22, 73.45)	59.78 (10.33, 44.76)	128.05 (27.20, 122.24)	< 0.001	0.004	< 0.001
MCP1	477.00 (397.19, 545.00)	591.61 (399.55, 779.32)	613.28 (430.85, 791.37)	844.96 (522.41, 990.98)	0.053	0.020	< 0.001
TNFa	8.61 (6.20, 10.95)	21.76 (8.93, 21.22)	12.45 (4.91, 14.84)	26.68 (13.88, 28.94)	< 0.001	0.006	< 0.001
VEGFA	102.78 (35.76, 118.27)	109.85 (34.53, 127.69)	118.44 (27.54, 188.60)	125.93 (19.54, 140.49)	0.499	0.603	0.390

#### 1316 Table S8. Accuracy, Precision, Recall and F1-score of symbolic classification in CDI

- 1317 diagnosis. CDI subjects were considered as either true positive or true negative. Results shown
- in the parenthesis represents the latter case. The performance of the symbolic classification
- 1319 model evaluated by cross-validation. We randomly split the dataset to form a training set (80%
- 1320 of the data) and a test set (20% of the data) in 10 different ways. Each time, for each
- 1321 classification task (diagnostic goal), we learned the SC model from the training dataset and
- 1322 evaluated it on the test dataset. Data represents as mean  $\pm$  standard deviation.
- 1323

Diagnostic goal	Accuracy	Precision	Recall	F1-score
CDI vs.		$0.878 \pm 0.101$	$0.963 \pm 0.043$	$0.915 \pm 0.061$
Asymptomatic	$0.873 \pm 0.085$	$0.070 \pm 0.101$	$0.903 \pm 0.043$	$0.913 \pm 0.001$
Carriage		$(0.857 \pm 0.180)$	$(0.639 \pm 0.229)$	$(0.718 \pm 0.185)$
CDI vs. Non-	$0.992 \pm 0.026$	$0.899\pm0.078$	$0.912\pm0.070$	$0.901 \pm 0.039$
CDI Diarrhea	$0.883 \pm 0.030$	$(0.865 \pm 0.098)$	$(0.847 \pm 0.110)$	$(0.846 \pm 0.055)$
CDI vs. Non-	0.010 + 0.040	$0.770 \pm 0.102$	$0.784 \pm 0.120$	$0.769\pm0.074$
CDI	$0.818 \pm 0.040$	(0.861 ±0.059)	$(0.839 \pm 0.091)$	$(0.845 \pm 0.036)$

1324

1325